Who Generates More Revenue? PTC Therapeutics, Inc. or Dynavax Technologies Corporation

Biotech Revenue Battle: PTC vs. Dynavax

__timestampDynavax Technologies CorporationPTC Therapeutics, Inc.
Wednesday, January 1, 20141103200022963000
Thursday, January 1, 2015405000036766000
Friday, January 1, 20161104300082705000
Sunday, January 1, 2017327000194392000
Monday, January 1, 20188198000264734000
Tuesday, January 1, 201935219000306980000
Wednesday, January 1, 202046551000380766000
Friday, January 1, 2021439442000538593000
Saturday, January 1, 2022722683000698801000
Sunday, January 1, 2023232284000937822000
Loading chart...

Igniting the spark of knowledge

Revenue Race: PTC Therapeutics vs. Dynavax Technologies

In the competitive landscape of biotechnology, revenue generation is a key indicator of success. Over the past decade, PTC Therapeutics, Inc. and Dynavax Technologies Corporation have been vying for dominance. From 2014 to 2023, PTC Therapeutics consistently outperformed Dynavax, with revenue peaking at approximately 938 million in 2023, a staggering 300% increase from 2014. In contrast, Dynavax saw a significant surge in 2022, reaching around 723 million, but fell to 232 million in 2023.

PTC's steady growth, particularly from 2017 onwards, highlights its strategic advancements in the biotech sector. Meanwhile, Dynavax's revenue spike in 2021 and 2022 suggests a temporary boost, possibly due to market-specific factors. This data underscores the dynamic nature of the biotech industry, where innovation and market conditions can dramatically shift revenue trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025